Literature DB >> 21832278

Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Hui Zheng1, Juan Qian, Christopher J Carbone, N Adrian Leu, Darren P Baker, Serge Y Fuchs.   

Abstract

Angiogenesis is stimulated by vascular endothelial growth factor (VEGF) and antagonized by type 1 interferons, including IFN-α/β. On engaging their respective receptors (VEGFR2 and IFNAR), both stimuli activate protein kinase D2 (PKD2) and type 1 IFNs require PKD2 activation and recruitment to IFNAR1 to promote the phosphorylation-dependent ubiquitination, down-regulation, and degradation of the cognate receptor chain, IFNAR1. Data reveal that PKD2 activity is dispensable for VEGF-stimulated down-regulation of VEGFR2. Remarkably, VEGF treatment promotes the recruitment of PKD2 to IFNAR1 as well as ensuing phosphorylation, ubiquitination, and degradation of IFNAR1. In cells exposed to VEGF, phosphorylation-dependent degradation of IFNAR1 leads to an inhibition of type 1 IFN signaling and is required for efficient VEGF-stimulated angiogenesis. Importance of this mechanism for proangiogenic or antiangiogenic responses in cells exposed to counteracting stimuli and the potential medical significance of this regulation are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21832278      PMCID: PMC3193273          DOI: 10.1182/blood-2011-06-359745

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  Signaling from across the way: transactivation of VEGF receptors by HSPGs.

Authors:  Scott B Selleck
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

4.  Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells.

Authors:  Meetha Medhora; John Daniels; Kavita Mundey; Beate Fisslthaler; Rudi Busse; Elizabeth R Jacobs; David R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-26       Impact factor: 4.733

5.  PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation.

Authors:  Rosana D Meyer; Srimathi Srinivasan; Amrik J Singh; John E Mahoney; Kobra Rezazadeh Gharahassanlou; Nader Rahimi
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

6.  Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor.

Authors:  K G Suresh Kumar; John J Krolewski; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2004-08-26       Impact factor: 5.157

7.  Stability of homologue of Slimb F-box protein is regulated by availability of its substrate.

Authors:  Ying Li; Stefan Gazdoiu; Zhen-Qiang Pan; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2004-01-05       Impact factor: 5.157

8.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

Review 9.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

10.  Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis.

Authors:  K G Suresh Kumar; Hervé Barriere; Christopher J Carbone; Jianghuai Liu; Gayathri Swaminathan; Ping Xu; Ying Li; Darren P Baker; Junmin Peng; Gergely L Lukacs; Serge Y Fuchs
Journal:  J Cell Biol       Date:  2007-12-03       Impact factor: 10.539

View more
  38 in total

Review 1.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

2.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

3.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

4.  Type 1 interferons contribute to the clearance of senescent cell.

Authors:  Yuliya V Katlinskaya; Christopher J Carbone; Qiujing Yu; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

5.  Ubiquitin-dependent Turnover of Adenosine Deaminase Acting on RNA 1 (ADAR1) Is Required for Efficient Antiviral Activity of Type I Interferon.

Authors:  Lemin Li; Guanghui Qian; Yibo Zuo; Yukang Yuan; Qiao Cheng; Tingting Guo; Jin Liu; Chang Liu; Liting Zhang; Hui Zheng
Journal:  J Biol Chem       Date:  2016-10-11       Impact factor: 5.157

6.  Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies.

Authors:  Zhen Lu; Angelica Ortiz; Ioannis I Verginadis; Amy R Peck; Farima Zahedi; Christina Cho; Pengfei Yu; Rachel M DeRita; Hongru Zhang; Ryan Kubanoff; Yunguang Sun; Andrew T Yaspan; Elise Krespan; Daniel P Beiting; Enrico Radaelli; Sandra W Ryeom; J Alan Diehl; Hallgeir Rui; Constantinos Koumenis; Serge Y Fuchs
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

7.  Lymphatic Vessels Balance Viral Dissemination and Immune Activation following Cutaneous Viral Infection.

Authors:  Christopher P Loo; Nicholas A Nelson; Ryan S Lane; Jamie L Booth; Sofia C Loprinzi Hardin; Archana Thomas; Mark K Slifka; Jeffrey C Nolz; Amanda W Lund
Journal:  Cell Rep       Date:  2017-09-26       Impact factor: 9.423

8.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

10.  Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Authors:  Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs
Journal:  J Invest Dermatol       Date:  2016-06-29       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.